Patients diagnosed with either, invasive ductal carcinoma (IDC) or ductal carcinoma in situ
(DCIS), were included in this study as it aims to investigate if there
is a correlation between zearalenone, its metabolites and breast
cancer, independently of the type or grade of cancer.